CRVS
Corvus Pharmaceuticals, Inc. · Healthcare
Orbimed Advisors LLC sold $6.8M of Corvus Pharmaceuticals, Inc.
Director and 10% owner
Sold$6,757,732
$6.09Price
1,109,644Shares
−14%Stake
What CRVS did after the filing
- The stock from Thu, Sep 23 open, $7.21
- −28.4%
- S&P 500, same days
- +6.2%
Measured over 30 trading days, to the Nov 4 close.
Traded Mon, Sep 20. Filed Wed, Sep 22, 5:27 PM ET, after the close. Returns use the Sep 23 open and the Nov 4 close. Not investment advice.